4,76 $
1,06 % gestern
Nasdaq, 8. Oktober, 22:00 Uhr
ISIN
US30049G1040
Symbol
EVOK
Berichte

Evoke Pharma, Inc. Aktie News

Neutral
Business Wire
5 Tage alt
LOS ANGELES--(BUSINESS WIRE)--Ranking recognizes Evoke's achievement in advancing client experience, and its leadership as a trusted advisor in the RIA industry.
Neutral
Business Wire
etwa ein Monat alt
CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.
Neutral
GlobeNewsWire
etwa ein Monat alt
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI®...
Neutral
GlobeNewsWire
etwa 2 Monate alt
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe sympt...
Neutral
GlobeNewsWire
2 Monate alt
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection
Neutral
GlobeNewsWire
3 Monate alt
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent applicatio...
Neutral
GlobeNewsWire
5 Monate alt
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results ...
Neutral
GlobeNewsWire
5 Monate alt
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has be...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen